Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2024/02/062496
CTRI/2024/02/062496
Not yet recruiting
Phase 2

Clinical study to evaluate the therapeutic safety and efficacy of Habb-e-Mafasil in the management of Waja’al- Rukba (Primary KneeOsteoarthritis): An open label block randomized standard control study. - NI

Central Council for Research In Unani Medicine New Delhi0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealth Condition 1: M170- Bilateral primary osteoarthritis of knee

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Health Condition 1: M170- Bilateral primary osteoarthritis of knee
Sponsor
Central Council for Research In Unani Medicine New Delhi
Status
Not yet recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Central Council for Research In Unani Medicine New Delhi

Eligibility Criteria

Inclusion Criteria

  • •patients irrespective of gender in the age group of 20 to 65 years will be included. clically and radiologically diagnosed patients with kellegren\-lawrence grades 1,2 and 3 and with BMI less than 35 kg per meter square. patients who have agreed to sign the informed consent form and are willing to follow up as per the study protocol.

Exclusion Criteria

  • •1\. Kellgren\- Lawrence grade 4 knee osteoarthritis.
  • •2\. Pregnant and Lactating women.
  • •3\. BMI more than 35kg per meter square.
  • •4\. History of recent knee infection.
  • •5\. Prior knee surgery.
  • •6\. Prior bone disease such as Osteomyelitis
  • •7\. Prior trauma to the knee joint.
  • •8\. Patients having received intra\-articular knee injection as that of corticosteroids or hyaluronic acid or any investigational drug in the past one month.
  • •9\. Known cases of inflammatory joint disease as Rheumatoid Arthritis.
  • •10\. Patients with history of any significant systemic diseases like cardiovascular, gastrointestinal, renal, hepatic.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 3
A Clinical Study to Evaluate the Safety and Efficacy of Livercure Tablets on Patients with Liver Cirrhosis.Health Condition 1: K745- Biliary cirrhosis, unspecifiedHealth Condition 2: K745- Biliary cirrhosis, unspecified
CTRI/2022/07/043725Jammi Pharmaceuticals Pvt Ltd
Completed
Phase 2
Clinical study to evaluate the safety and efficacy of cinnamon in the management of non-alcoholic fatty liver diseaseHealth Condition 1: K760- Fatty (change of) liver, not elsewhere classified
CTRI/2021/03/032039Central council for research in Unani medicine New dehli60
Completed
Not Applicable
To study the effect of Tab HFO-O2 in fatty individuals.
CTRI/2016/07/007067Baidyanath Bhavan Pvt Ltd
Recruiting
Phase 2
Clinical study to evaluate the safety and efficacy of Lunagel 2.5 dermal filler
IRCT20190210042676N33ikan Teb Kimia CO30
Unknown
Phase 3
Clinical study to evaluate the efficacy and safety of TA-650 in patients with psoriasisPsoriasis
JPRN-jRCT2080220313Mitsubishi Tanabe Pharma Corporation